LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Kodu・Aktsiate loetelu・IQVIA Holdings Inc

IQVIA Holdings Inc

Avatud

Sektor Tervishoid

210.38 0.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

204.7

Max

210.76

Põhinäitajad
By Trading Economics
Sissetulek	-78M 285M
Müük	90M 3.9B
P/E Sektori keskmine	28.89 104.138
Aktsiakasum	2.84
Kasumimarginaal	7.308
Töötajad	87,000
EBITDA	-12M 856M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+24.53 upside

Turustatistika
By TradingEconomics
Turukapital	-4.9B 37B
Eelmine avamishind	209.81
Eelmine sulgemishind	210.38

Uudiste sentiment

By Acuity

50%

167 / 390 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

200.3 / 214.63 Toetus ja vastupanu

IQVIA Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2024, 23:05 UTC

Peamised uudised

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3. nov 2024, 21:12 UTC

Tulu

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3. nov 2024, 20:59 UTC

Tulu

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3. nov 2024, 23:34 UTC

Peamised uudised

Stocks Poised for Lower Open -- Barrons.com

3. nov 2024, 23:16 UTC

Peamised uudised

Tulu

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3. nov 2024, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Working Interest in PNG LNG Now 39.9%

3. nov 2024, 22:50 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3. nov 2024, 22:49 UTC

Omandamised, ülevõtmised, äriostud

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3. nov 2024, 22:49 UTC

Omandamised, ülevõtmised, äriostud

Santos Receives Final $241 Million Payment From Kumul

3. nov 2024, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3. nov 2024, 20:37 UTC

Tulu

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3. nov 2024, 20:36 UTC

Tulu

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3. nov 2024, 20:35 UTC

Tulu

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3. nov 2024, 20:35 UTC

Tulu

Westpac Raises Share Buyback Program by A$1 Billion

3. nov 2024, 20:35 UTC

Tulu

Westpac Final Dividend A$0.76/Share

3. nov 2024, 20:33 UTC

Tulu

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3. nov 2024, 20:32 UTC

Tulu

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3. nov 2024, 20:32 UTC

Tulu

Westpac FY Net Profit A$6.99 Billion, Down 3%

3. nov 2024, 18:09 UTC

Peamised uudised

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3. nov 2024, 10:30 UTC

Peamised uudised

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3. nov 2024, 03:00 UTC

Peamised uudised

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2. nov 2024, 13:53 UTC

Peamised uudised

Tulu

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2. nov 2024, 13:44 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 13:00 UTC

Peamised uudised

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2. nov 2024, 12:58 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. nov 2024, 12:48 UTC

Peamised uudised

Tulu

Omandamised, ülevõtmised, äriostud

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2. nov 2024, 12:32 UTC

Tulu

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

IQVIA Holdings Inc Prognoos

Hinnasiht

By TipRanks

24.53% tõus

12 kuu keskmine prognoos

Keskmine 260.46 USD 24.53%

Kõrge 279 USD

Madal 235 USD

Põhineb 14 Wall Streeti analüütiku instrumendi IQVIA Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi IQVIA Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

200.3 / 214.63Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

167 / 390 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest IQVIA Holdings Inc

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company's life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.